Merck halts vibostolimab and favezelimab trials due to efficacy results, prioritizing its oncology pipeline while the FDA reviews RSV drug clesrovimab.
Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis
Where Today's News Shapes Tomorrow
